Supply of cilazapril with hydrochlorothiazide
Cilazapril with hydrochlorothiazide is a medicine used for the treatment of patients with hypertension who are not adequately controlled on monotherapy. This medicine may also be used for other indications.
Apotex, the supplier of cilazapril with hydrochlorothiazide has informed PHARMAC it will no longer be able to supply this medicine in New Zealand. The current supply is likely to run out in July 2020.
Apo-Cilazapril/Hydrochlorothiazide is the only Medsafe registered brand of cilazapril with hydrochlorothiazide tablets in New Zealand. This means cilazapril with hydrochlorothiazide will no longer be available to patients once the current supply runs out. New patient initiations will be restricted.
Please note that this discontinuation does not apply to cilazapril tablets without hydrochlorothiazide.
The future of cilazapril
Supplies of cilazapril tablets have been secured until 2022. Cilazapril is used infrequently or not at all in other countries and we are aware of only one manufacturer of the active ingredient internationally.
This means if a supply issue were to occur, then it would likely be difficult to resolve or mitigate. This could have a significant impact on patients and health care professionals.
When prescribing an ACE inhibitor, consider prescribing a different one than cilazapril.
When will cilazapril with hydrochlorothiazide be unavailable?
- From 1 March 2020, cilazapril with hydrochlorothiazide will no longer be funded for new patients.
- From July 2020, current cilazapril with hydrochlorothiazide stocks are likely to run out.
From 1 March 2020, prescribers will need to endorse any prescriptions for cilazapril with hydrochlorothiazide for patients who were taking this medicine prior to 1 March 2020.
Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of cilazapril with hydrochlorothiazide.
People taking cilazapril with hydrochlorothiazide will need to talk to their health care professional about alternative treatments.
Information for health care professionals
Prescribers will need to:
- ensure no new patients are started on cilazapril with hydrochlorothiazide from 1 March 2020.
- start transitioning patients currently on cilazapril with hydrochlorothiazide to alternative treatments.
What are the funded treatment options?
Based on advice we have received from our expert clinical advisors, alternative treatment options for cilazapril with hydrochlorothiazide include:
- A suitable fully funded alternative angiotensin II antagonist with diuretic would be losartan with hydrochlorothiazide
- A suitable fully funded alternative ACE inhibitor with diuretic would be quinapril with hydrochlorothiazide
Cilazapril with hydrochlorothiazide
Quinapril with hydrochlorothiazide
Losartan with hydrochlorothiazide
(Arrow-Losartan & Hydrochlorothiazide)
Approximate Equivalent Strength
5 mg cilazapril with
12.5 mg hydrochlorothiazide
20 mg* quinapril with
50 mg losartan with
For the treatment of hypertension not adequately controlled with monotherapy
When changing patients to another fixed dose combination it is recommended to monitor blood pressure and renal function (creatinine and electrolytes).
A fixed dose combination would be the preferred alternative to cilazapril with hydrochlorothiazide, although some people may prefer to change to two separate medicines (i.e. an ACE inhibitor and a separate diuretic). Currently cilazapril is used infrequently or not at all in other countries and we are aware of only one manufacturer of the active ingredient internationally. For this reason, alternative treatment agents should be considered. There are a number of different funded ACE inhibitors and one of these could be prescribed together with a funded thiazide or thiazide-like diuretic.
Information for people taking cilazapril with hydrochlorothiazide
Cilazapril with hydrochlorothiazide is used to treat people with high blood pressure and may also be used for other conditions.
The supplier of cilazapril with hydrochlorothiazide (Apotex) has informed PHARMAC it will no longer be able to supply this medicine in New Zealand. The current supply is likely to run out in July 2020.
No other brands of this medication are available, you will need to change to a different ACE inhibitor once the current supply runs out.
If you take cilazapril with hydrochlorothiazide, talk to your health care professional about alternative treatments.
When will this happen
We expect stocks to run out by July 2020. We recommend you talk to your health care professional before this to manage your move to a different medicine.
From 1 March 2020, new patients will not be funded for cilazapril with hydrochlorothiazide.
What are the funded treatment options?
There are a number of fully funded treatment options. You will need to talk to your health care professional to find out which is best for you.
Who to contact
If you have any questions, contact PHARMAC on:
Last updated: 12 February 2020